Duration of checkpoint inhibitor therapy
17 May 2017
Duration of checkpoint inhibitor therapy
PD1/ CTLA4 : Upfront or sequentially?
Deregulated TGF-β superfamily signalling in cancer
The potential of aspirin in the prevention and treatment of cancer
Functions of BRCA1 and the implications for treatment
Genetic determinants of breast cancer immune phenotypes
IMPAKT conference highlights
Mutational landscapes in pregnant and non-pregnant breast cancer
Resistance to CDK4/6 inhibitors
Deciphering the connection of genetics, immune infiltration and prognosis
Genetic vs immune strategies in breast cancer
Transforming patient care through translational research